Any self-medicationa before consultation |
Country | | | | | | | | |
The Netherlands (reference) | 164 (59.2) | | | | | | | |
Belgium | 176 (53.8) | | 0.803 | 0.581 to 1.110 | 0.184 | 0.850 | 0.607 to 1.190 | 0.344 |
England | 119 (60.7) | | 1.065 | 0.733 to 1.547 | 0.742 | 0.995 | 0.673 to 1.471 | 0.980 |
France | 21 (70.0) | | 1.608 | 0.710 to 3.639 | 0.255 | 1.435 | 0.629 to 3.275 | 0.391 |
Germany | 84 (49.1) | | 0.665 | 0.453 to 0.977 | 0.037 | 0.634 | 0.428 to 0.938 | 0.023 |
Italy | 23 (53.5) | | 0.792 | 0.416 to 1.511 | 0.480 | 1.036 | 0.531 to 2.020 | 0.917 |
Poland | 299 (59.1) | | 0.995 | 0.739 to 1.341 | 0.975 | 1.011 | 0.743 to 1.375 | 0.946 |
Slovakia | 42 (32.3) | | 0.329 | 0.212 to 0.510 | <0.001 | 0.296 | 0.189 to 0.463 | <0.001 |
Slovenia | 45 (65.2) | | 1.292 | 0.745 to 2.240 | 0.362 | 1.406 | 0.803 to 2.460 | 0.233 |
Spain | 283 (57.5) | | 0.933 | 0.692 to 1.258 | 0.649 | 0.961 | 0.706 to 1.307 | 0.799 |
Sweden | 65 (70.7) | | 1.659 | 0.997 to 2.759 | 0.051 | 1.450 | 0.862 to 2.439 | 0.161 |
Wales | 81 (41.1) | | 0.481 | 0.332 to 0.698 | <0.001 | 0.474 | 0.325 to 0.693 | <0.001 |
Male sex | Male: 497 (48.9); Female: 905 (59.8) | | 0.642 | 0.547 to 0.754 | <0.001 | 0.730 | 0.617 to 0.864 | <0.001 |
Ageb | | | 0.995 | 0.990 to 0.999 | 0.027 | 0.997 | 0.991 to 1.002 | 0.225 |
Current smoking | Yes: 352 (51.9); No: 1049 (56.7) | 1 (0.0) | 0.826 | 0.692 to 0.985 | 0.033 | 0.756 | 0.625 to 0.914 | 0.004 |
Presence of comorbidity | Yes: 372 (52.6); No: 1029 (56.6) | 4 (0.2) | 0.853 | 0.716 to 1.015 | 0.073 | 0.888 | 0.734 to 1.074 | 0.221 |
Symptom severity scorec | | 47 (1.9) | 1.016 | 1.010 to 1.021 | <0.001 | 1.018 | 1.012 to 1.024 | <0.001 |
|
Any self-medicationa after consultation |
Country | | | | | | | | |
The Netherlands (reference) | 62 (22.4) | | | | | | | |
Belgium | 94 (28.7) | | 1.399 | 0.966 to 2.026 | 0.076 | 1.451 | 0.983 to 2.141 | 0.061 |
England | 73 (37.2) | | 2.058 | 1.373 to 3.084 | <0.001 | 1.595 | 1.037 to 2.453 | 0.033 |
France | 6 (20.0) | | 0.867 | 0.339 to 2.215 | 0.765 | 0.847 | 0.328 to 2.183 | 0.730 |
Germany | 31 (18.1) | | 0.768 | 0.475 to 1.242 | 0.282 | 0.729 | 0.439 to 1.212 | 0.223 |
Italy | 8 (18.6) | | 0.793 | 0.350 to 1.797 | 0.578 | 0.721 | 0.293 to 1.776 | 0.478 |
Poland | 113 (22.3) | | 0.997 | 0.702 to 1.417 | 0.987 | 1.021 | 0.708 to 1.472 | 0.912 |
Slovakia | 34 (26.2) | | 1.228 | 0.758 to 1.990 | 0.404 | 1.166 | 0.710 to 1.914 | 0.544 |
Slovenia | 18 (26.1) | | 1.224 | 0.667 to 2.246 | 0.514 | 1.140 | 0.609 to 2.132 | 0.682 |
Spain | 49 (10.0) | | 0.384 | 0.255 to 0.577 | <0.001 | 0.412 | 0.269 to 0.629 | <0.001 |
Sweden | 17 (18.5) | | 0.786 | 0.432 to 1.429 | 0.430 | 0.676 | 0.364 to 1.256 | 0.216 |
Wales | 40 (20.3) | | 0.884 | 0.565 to 1.382 | 0.588 | 0.825 | 0.518 to 1.314 | 0.418 |
Male sex | Male: 181 (17.8); Female: 364 (24.1) | | 0.683 | 0.560 to 0.834 | <0.001 | 0.719 | 0.582 to 0.888 | 0.002 |
Ageb | | | 0.994 | 0.988 to 1.000 | 0.038 | 0.996 | 0.990 to 1.003 | 0.255 |
Current smoking | Yes: 121 (17.8); No: 424 (22.9) | 1 (0.0) | 0.731 | 0.584 to 0.915 | 0.006 | 0.690 | 0.541 to 0.879 | 0.003 |
Presence of comorbidity | Yes: 138 (19.5); No: 405 (22.3) | 4 (0.2) | 0.847 | 0.682 to 1.051 | 0.132 | 0.901 | 0.712 to 1.140 | 0.385 |
Symptom severity scorec | | 47 (1.9) | 1.015 | 1.008 to 1.021 | <0.001 | 1.014 | 1.007 to 1.021 | <0.001 |
Medication prescribed | Yes: 351 (19.5); No: 191 (26.4) | 5 (0.2) | 0.674 | 0.550 to 0.825 | <0.001 | 0.716 | 0.565 to 0.907 | 0.006 |
Participation in trial | Yes: 381 (22.6); No: 164 (19.4) | | 1.219 | 0.993 to 1.496 | 0.059 | 0.983 | 0.770 to 1.255 | 0.891 |